Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

Epilepsia

Volumn 52, Issue 7, 2011, Pages 1331-1340

  Hanada, Takahisa ^a   Hashizume, Yutaka ^a   Tokuhara, Naoki ^a   Takenaka, Osamu ^a   Kohmura, Naohiro ^a   Ogasawara, Aichi ^a   Hatakeyama, Shinji ^a   Ohgoh, Makoto ^a   Ueno, Masataka ^a   Nishizawa, Yukio ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Antiepileptic agent; Antiseizure; Broad spectrum

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; GLUTAMIC ACID; PENTETRAZOLE; PERAMPANEL;

AMYGDALOID NUCLEUS; ARTICLE; BRAIN CELL; BRAIN CORTEX; BRAIN MEMBRANE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; ELECTRIC SHOCK; FOCAL EPILEPSY; FOREBRAIN; IC 50; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

AMYGDALA; ANIMALS; ANTICONVULSANTS; BRAIN; CALCIUM; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOGS; INTRACELLULAR SPACE; MALE; MICE; NEURONS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, AMPA; SEIZURES;

EID: 79959970405     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03109.x     Document Type: Article

References (35)

1. Abe K, Takayanagi M, Saito H,. (1990) Effects of recombinant human basic fibroblast growth factor and its modified protein CS23 on survival of primary cultured neurons from various regions of fetal rat brain. Jpn J Pharmacol 53: 221-227. (Pubitemid 20184419)
2. Arroyo S, Lesser RP,. (1993) PET, MRI, and epilepsy. Neurology 43: 2156.
3. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S,. (2004) Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45: 20-27. (Pubitemid 38063660)
4. Balannik V, Menniti FS, Paternain AV, Lerma J, Stern-Bach Y,. (2005) Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron 48: 279-288. (Pubitemid 41476361)
5. Barton ME, White HS,. (2004) The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res 59: 1-12. (Pubitemid 38595416)
6. Barton ME, Klein BD, Wolf HH, White HS,. (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47: 217-227. (Pubitemid 34008465)
7. Barton ME, Peters SC, Shannon HE,. (2003) Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res 56: 17-26. (Pubitemid 37177052)
8. Bialer M, White HS,. (2010) Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Disc 9: 68-82.
9. Browne TR, Holmes GL,. (2001) Epilepsy. N Engl J Med 344: 1145-1151.
10. Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, Bjerke J, Kiesler GM, Arroyo S,. (2002) A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58: 1680-1682. (Pubitemid 34602903)
11. Dalby NO, Nielsen EB,. (1997) Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 28: 63-72. (Pubitemid 27306795)
12. Danober L, Deransart C, Depaulis A, Vergnes M, Marescaux C,. (1998) Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog Neurobiol 55: 27-57. (Pubitemid 28231101)
13. Donevan SD, Rogawski MA,. (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10: 51-59. (Pubitemid 23045425)
14. Ebert U, Cramer S, Loscher W,. (1997) Phenytoin's effect on the spread of seizure activity in the amygdala kindling model. Naunyn Schmiedebergs Arch Pharmacol 356: 341-347. (Pubitemid 27376465)
15. Fischer W, Allgaier C, Illes P,. (2000) Inhibition by chloral hydrate and trichloroethanol of AMPA-induced Ca(2+) influx in rat cultured cortical neurones. Eur J Pharmacol 394: 41-45. (Pubitemid 30193286)
16. French JA, Faught E,. (2009) Refractory seizures: rational polytherapy. Epilepsia 50 (Suppl. 8): 63-68.
17. Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA,. (2010) Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia 51: 108-117.
18. Hara H, Yamada N, Kodama M, Matsumoto Y, Wake Y, Kuroda S,. (2006) Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy. Eur J Pharmacol 531: 59-65. (Pubitemid 43202216)
19. Howes JF, Bell C,. (2007) Talampanel. Neurotherapeutics 4: 126-129. (Pubitemid 46107320)
20. Jonker DM, Voskuyl RA, Danhof M,. (2007) Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 48: 412-434. (Pubitemid 46365183)
21. Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW, Patsalos PN,. (2003) Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 44: 46-53. (Pubitemid 36733620)
22. Löscher W,. (2002) Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 50: 105-123. (Pubitemid 34876591)
23. Mattson RH, Cramer JA, Collins JF,. (1992) A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The department of veterans affairs epilepsy cooperative study no. 264 group. N Engl J Med 327: 765-771.
24. Meldrum BS, Rogawski MA,. (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4: 18-61. (Pubitemid 46107329)
25. Namba T, Morimoto K, Sato K, Yamada N, Kuroda S,. (1994) Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res 638: 36-44. (Pubitemid 24063285)
26. Perucca E, French J, Bialer M,. (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6: 793-804. (Pubitemid 47243712)
27. Rogawski MA,. (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69: 273-294. (Pubitemid 44209049)
28. Rogawski MA, Donevan SD,. (1999) AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv Neurol 79: 947-963.
29. Scharfman HE,. (2007) The neurobiology of epilepsy. Curr Neurol Neurosci Rep 7: 348-354. (Pubitemid 47098457)
30. Stafstrom CE,. (2010) Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol 23: 157-163.
31. Tortorella A, Halonen T, Sahibzada N, Gale K,. (1997) A crucial role of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype of glutamate receptors in piriform and perirhinal cortex for the initiation and propagation of limbic motor seizures. J Pharmacol Exp Ther 280: 1401-1405. (Pubitemid 27166738)
32. Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, Taylor CP,. (2006) Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res 68: 189-205.
33. Weiser T,. (2005) AMPA receptor antagonists for the treatment of stroke. Curr Drug Targets CNS Neurol Disord 4: 153-159. (Pubitemid 40601606)
34. Yamaguchi S, Donevan SD, Rogawski MA,. (1993) Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 15: 179-184. (Pubitemid 23271758)
35. Yen W, Williamson J, Bertram EH, Kapur J,. (2004) A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus. Epilepsy Res 59: 43-50. (Pubitemid 38595420)